Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patent-plea-on-vaccine-hits-block-4678843/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patent-plea-on-vaccine-hits-block-4678843/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patent-plea-on-vaccine-hits-block-4678843/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patent-plea-on-vaccine-hits-block-4678843/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-trace').style.display = (document.getElementById('cakeErr67ea1e2735645-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ea1e2735645-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-code').style.display = (document.getElementById('cakeErr67ea1e2735645-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-context').style.display = (document.getElementById('cakeErr67ea1e2735645-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ea1e2735645-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ea1e2735645-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 30778,
		&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4678843,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 30778,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 30778,
	&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4678843,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 30778
$metaTitle = &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;
$metaKeywords = &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-plea-on-vaccine-hits-block-4678843.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent plea on vaccine hits block | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent plea on vaccine hits block</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br /><br />The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br /><br />The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br /><br />&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br /><br />Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br /><br />An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br /><br />&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br /><br />MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br /><br />&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br /><br />Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br /><br />They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br /><br />Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-trace').style.display = (document.getElementById('cakeErr67ea1e2735645-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ea1e2735645-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-code').style.display = (document.getElementById('cakeErr67ea1e2735645-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-context').style.display = (document.getElementById('cakeErr67ea1e2735645-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ea1e2735645-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ea1e2735645-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 30778,
		&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4678843,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 30778,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 30778,
	&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4678843,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 30778
$metaTitle = &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;
$metaKeywords = &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-plea-on-vaccine-hits-block-4678843.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent plea on vaccine hits block | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent plea on vaccine hits block</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br /><br />The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br /><br />The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br /><br />&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br /><br />Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br /><br />An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br /><br />&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br /><br />MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br /><br />&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br /><br />Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br /><br />They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br /><br />Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-trace').style.display = (document.getElementById('cakeErr67ea1e2735645-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ea1e2735645-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-code').style.display = (document.getElementById('cakeErr67ea1e2735645-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ea1e2735645-context').style.display = (document.getElementById('cakeErr67ea1e2735645-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ea1e2735645-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ea1e2735645-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 30778,
		&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4678843,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 30778,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 30778,
	&#039;title&#039; =&gt; &#039;Patent plea on vaccine hits block&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;
&lt;br /&gt;
The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;
&lt;br /&gt;
The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;
&lt;br /&gt;
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;
&lt;br /&gt;
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;
&lt;br /&gt;
Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;
&lt;br /&gt;
They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;
&lt;br /&gt;
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-plea-on-vaccine-hits-block-4678843&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4678843,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 30778
$metaTitle = &#039;LATEST NEWS UPDATES | Patent plea on vaccine hits block&#039;
$metaKeywords = &#039;Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.&lt;br /&gt;&lt;br /&gt;The patent opposition moved by MSF has claimed that Pfizer&#039;s patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India&#039;s patent laws.&lt;br /&gt;&lt;br /&gt;The agency said its opposition to the patent follows &amp;quot;years of fruitless negotiations&amp;quot; with Pfizer to lower the vaccine&#039;s price. &amp;quot;(Pfizer&#039;s) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&amp;quot; Leena Menghaney, head of the MSF&#039;s access campaign, told The Telegraph.&lt;br /&gt;&lt;br /&gt;&amp;quot;We&#039;re opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&amp;quot;&lt;br /&gt;&lt;br /&gt;Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine&#039;s cost puts it out of the reach of many in developing countries.&lt;br /&gt;&lt;br /&gt;An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.&lt;br /&gt;&lt;br /&gt;&amp;quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&amp;quot; Manica Balasegaram, executive director of MSF&#039;s access campaign, said in a statement.&lt;br /&gt;&lt;br /&gt;MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.&lt;br /&gt;&lt;br /&gt;&amp;quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&amp;quot; Menghaney said.&lt;br /&gt;&lt;br /&gt;Patients&#039; rights activists and agencies such as MSF have long campaigned for Indian companies&#039; right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.&lt;br /&gt;&lt;br /&gt;They have urged the Indian patent office to rigorously apply section 3(d) of India&#039;s patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.&lt;br /&gt;&lt;br /&gt;Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-plea-on-vaccine-hits-block-4678843.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent plea on vaccine hits block | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent plea on vaccine hits block</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br /><br />The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br /><br />The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br /><br />&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br /><br />Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br /><br />An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br /><br />&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br /><br />MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br /><br />&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br /><br />Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br /><br />They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br /><br />Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 30778,
		'title' => 'Patent plea on vaccine hits block',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph<br />
<br />
<em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br />
<br />
The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br />
<br />
The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br />
<br />
&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br />
<br />
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br />
<br />
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br />
<br />
&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br />
<br />
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br />
<br />
&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br />
<br />
Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br />
<br />
They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br />
<br />
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
</div>',
		'credit_writer' => 'The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'patent-plea-on-vaccine-hits-block-4678843',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4678843,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 30778,
	'metaTitle' => 'LATEST NEWS UPDATES | Patent plea on vaccine hits block',
	'metaKeywords' => 'Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres',
	'metaDesc' => '
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...',
	'disp' => '<div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br /><br />The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br /><br />The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br /><br />&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br /><br />Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br /><br />An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br /><br />&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br /><br />MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br /><br />&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br /><br />Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br /><br />They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br /><br />Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 30778,
	'title' => 'Patent plea on vaccine hits block',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph<br />
<br />
<em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br />
<br />
The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br />
<br />
The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br />
<br />
&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br />
<br />
Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br />
<br />
An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br />
<br />
&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br />
<br />
MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br />
<br />
&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br />
<br />
Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br />
<br />
They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br />
<br />
Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.
</div>',
	'credit_writer' => 'The Telegraph, 12 March, 2016, http://www.telegraphindia.com/1160313/jsp/nation/story_74268.jsp#.VuVtO-Y1t_k',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'patent-plea-on-vaccine-hits-block-4678843',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4678843,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 30778
$metaTitle = 'LATEST NEWS UPDATES | Patent plea on vaccine hits block'
$metaKeywords = 'Pneumonia,Intellectual Property Rights,IPRs,Doctors Without Borders,patents,Medecins Sans Frontieres'
$metaDesc = '
-The Telegraph

New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.

The patent...'
$disp = '<div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions.<br /><br />The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws.<br /><br />The agency said its opposition to the patent follows &quot;years of fruitless negotiations&quot; with Pfizer to lower the vaccine's price. &quot;(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended,&quot; Leena Menghaney, head of the MSF's access campaign, told The Telegraph.<br /><br />&quot;We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine.&quot;<br /><br />Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries.<br /><br />An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses.<br /><br />&quot;To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges,&quot; Manica Balasegaram, executive director of MSF's access campaign, said in a statement.<br /><br />MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India.<br /><br />&quot;Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law,&quot; Menghaney said.<br /><br />Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies.<br /><br />They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs.<br /><br />Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Patent plea on vaccine hits block

-The Telegraph New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions. The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not merit a patent under India's patent laws. The agency said its opposition to the patent follows "years of fruitless negotiations" with Pfizer to lower the vaccine's price. "(Pfizer's) vaccine is available in India through paediatricians for about Rs 4,000 a dose, and three doses are recommended," Leena Menghaney, head of the MSF's access campaign, told The Telegraph. "We're opposing the patent because we want Indian vaccine makers to be able to produce and sell low-cost versions of the vaccine." Pneumonia is a leading cause of childhood deaths worldwide. The vaccine, called PCV13, is designed to protect children from pneumonia caused by serotypes of S. pneumoniae. But MSF says the vaccine's cost puts it out of the reach of many in developing countries. An MSF statement said on Friday that a vaccine producer in India had said it could supply the pneumonia vaccine for $6 (Rs 402) per child for all three doses. "To make sure that children everywhere can be protected from deadly pneumonia, (more) companies need to enter the market to supply this vaccine for a much lower price than what Pfizer charges," Manica Balasegaram, executive director of MSF's access campaign, said in a statement. MSF has pointed out that the European Patent Office has revoked an equivalent patent to the one filed by Pfizer in India. "Our pre-grant opposition shows that the method Pfizer is trying to patent is too obvious to deserve a patent under Indian law," Menghaney said. Patients' rights activists and agencies such as MSF have long campaigned for Indian companies' right to produce cheaper generic versions of medicines originally developed and patented by foreign companies. They have urged the Indian patent office to rigorously apply section 3(d) of India's patent law, which can be used to deny patents to formulations that use minor tweaks to molecules of known drugs. Representatives of multinational drug companies have argued in the past that opposition to patents undermines the value and role of the research and investment that go into the development of new drugs and vaccines.